N/A N=15 Cryolipolysis for Jawline Contouring
Body Fat Disorder
Primary: Number of Participants With Unanticipated Adverse Device Effects (UADE) — 0 Participants with UADE reported
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
N/A N=16 Jowl Improvement With Injectable Fillers
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
N/A N=180 Evaluation of Effectiveness and Safety of Radiesse (+) to Improve the Contour of Jawline by Adding Volume to the Jawline
Improvement of Jawline Contour
Primary: Responder Rate According to the Merz Jawline Assessment Scale (MJAS) — 75.6; 8.8 percentage of participants — p=<0.0001
N/A N=224 To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition
Jawline Definition Deficiency
Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
N/A N=140 Effectiveness and Safety of Restylane Lyft Lidocaine for Jawline Definition
Jawline Definition
Primary: Percentage of Responders Having At Least a 1-Grade Improvement From Baseline on Both Jawlines Concurrently Based on Galderma Jawline Scale (GJS) at Month 3 as Assessed…
N/A N=29 Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline
Volume Loss of the Jawline
Primary: Percentage of Jawlines Achieving Greater Than or Equal to (>=) 1-point Improvement on Merz Jawline Grading Scale (MJGS) at Week 4 — 92.1; 0; 92.1; 0 percentage of…
Phase 3 N=206 Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
N/A N=32 Lifting and Tightening of the Face and Neck Following an Increased Density Treatment
Skin Laxity
Primary: Improvement in Overall Lifting and Tightening of Skin — 48 percentage of participants improved
N/A N=68 CONFORM: Rotational Fractional Resection for Submental Contouring
Skin Laxity · Lipodystrophy
Primary: Number of Participants With a Reduction of Submental Skin Area ≥ 20 mm^2 — 49 Participants
N/A N=148 Restylane Defyne for Correction of Chin Retrusion
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
N/A N=15 Clinical Assessment of Skin Tightening and Contour Change of Submental Tissue Using Bipolar Radiofrequency Microneedling
Skin Laxity
Primary: Percent Change From Baseline of Soft Tissue Surface Area — -0.18; -017 percent change
N/A N=201 Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
Healthy Volunteers
Primary: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS) — 0.728; 0.711 Kendall's W
N/A N=2 The PREFORM Study: Rotational Fractional Resection for Submental Contouring
Skin Laxity · Lipodystrophy
Primary: Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale — 2 Participants
N/A N=192 A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation
Chin Retrusion
Primary: Percentage of Participants With a ≥ 1-point Improvement (Decrease) on the Allergan Chin Retrusion Scale (ACSR) Score — 56.3; 27.5 percentage of participants — p=0.0019
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
N/A N=103 Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue
Mild to Moderate Skin Laxity on Cheek · Mild to Moderate Skin Laxity on Upper Neck · Mild to Moderate Subcutaneous Fat on Cheek
Primary: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions. — 68.60 percentage of participants improved
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
N/A N=52 Lifting and Tightening of the Face in Subjects With Skin of Darker Color
Facial Skin Laxity
Primary: Change in Overall Lifting and Tightening of Treated Tissue
Phase 4 N=20 Injectable Filler for Cheek Flattening
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
N/A N=175 Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile
Chin Augmentation · Chin Retrusion
Primary: Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3 — -0.94; -1.02 score on a scale
Phase 3 N=377 BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
Masseter Muscle Prominence
Primary: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90 — 2.2; 51.2 percentage of participants — p=<0.0001
N/A N=140 A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
Chin Retrusion · Chin Augmentation
Primary: Evaluate Effectiveness of the Treatment Using the Galderma Chin Restrusion Scale — 87; 2 Participants
N/A N=5 HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
Phase 3 N=25 Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Glabellar Frown Lines · Canthal Lines
Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
N/A N=270 GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
Cheek Augmentation
Primary: Assess Efficacy of Study Treatment Using Medicis Midface Volume Score (MMVS) — -1.4; -0.1; -1.3 score on a scale
N/A N=205 Sculptra for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
Midface Volume Deficit
Primary: Percentage of Participants With 1 Point Improvement From Baseline on the Medicis Midface Volume Scale (MMVS) as Measured by the Blinded Evaluator at Month 12 — 68.8…
N/A N=60 Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients
Mild to Moderate Skin Laxity Under the Chin · Mild to Moderate Skin Laxity on Neck
Primary: Mean Change From Baseline in Overall Lifting and Tightening of Submental (Under the Chin) and Neck Tissue Area at Day 90 Post-treatment — -14.4; -7.9; -22.3 square…
N/A N=225 Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing
Temporal Hollowing
Primary: Responder Rate Based on the Blinded Evaluators' Live Assessment of the Galderma Temple Volume Deficit Scale (GTVDS) — 91.2; 9.1 percentage of participants — p=<0.001
N/A N=14 Fat Reduction in the Submandibular/Submental Area
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos